Checkpoint blockade immunotherapy relies on T-betbutnoteomes to induceeffector functionin tumor-infiltrating CD8+ T cells

Cancer Immunology Research

Volumn 3, Issue 2, 2015, Pages 116-124

  Berrien Elliott, Melissa M ^a   Yuan, Jinyun ^a   Swier, Lauryn E ^a   Jackson, Stephanie R ^a   Chen, Collin L ^a   Donlin, Maureen J ^a   Teague, Ryan M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; LAG 3 PROTEIN; PEPTIDES AND PROTEINS; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; EOMES PROTEIN, MOUSE; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CHECKPOINT BLOCKADE IMMUNOTHERAPY; CONTROLLED STUDY; EFFECTOR CELL; IMMUNOLOGICAL TOLERANCE; INTERFERON PRODUCTION; LEUKEMIA; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN INDUCTION; TUMOR IMMUNITY; ANIMAL; CANCER TRANSPLANTATION; CYTOTOXICITY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, EXPERIMENTAL; PROCEDURES; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNE TOLERANCE; IMMUNOTHERAPY; LEUKEMIA, EXPERIMENTAL; LYMPHOCYTES, TUMOR-INFILTRATING; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; T-BOX DOMAIN PROTEINS;

EID: 84962278566     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0159     Document Type: Article

References (30)

1. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306.
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331: 1565-70.
3. Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer 2013;1:13.
4. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
5. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
6. +T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007;117:3383-92.
7. Jackson SR, Yuan J, Teague RM. Targeting CD8(+) T-cell tolerance for cancer immunotherapy. Immunotherapy 2014;6:833-52.
8. + T-cell tolerance. Cancer Res 2013;73:605-16.
9. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.
10. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72:917-27.
11. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
12. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
13. Gangadhar TC, Vonder heide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 2014;11:91-9.
14. + T cell function by the transcription factor Eomesodermin. Science 2003;302:1041-3.
15. + T cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005;6:1236-44.
16. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A 2003;100:15818-23.
17. + T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance. J Leukoc Biol 2014;96:397-410.
18. Zhu Y, Ju S, Chen E, Dai S, Li C, Morel P, et al. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol 2010;185:3174-83.
19. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
20. + T lymphocytes by repressing Eomesodermin. Eur J Immunol 2009;39:883-93.
21. Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, et al. Enhancement of tumor-reactive cytotoxic CD4 T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 2013;1:235-44.
22. Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, et al. The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 2012;37:660-73.
23. + T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation. J Immunol 2007;178: 6849-60.
24. + T cells lacking T-bet and eomesodermin. Science 2008;321:408-11.
25. Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, et al. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med 2011;208: 1605-20.
26. Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunol Res 2014;2: 970-80.
27. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710
28. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013;1:32-42.
29. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543-53.
30. Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15- responsive IFN-gamma-producing cells. Immunity 2013;38:769-81.